Subscribe
Home Economics Martin Shkreli: Daraprim Has Always Been Affordable

Martin Shkreli: Daraprim Has Always Been Affordable

When you purchase through our sponsored links, we may earn a commission. By using this website you agree to our T&Cs.

Martin Shkreli: Daraprim Has Always Been Affordable
Published on Nov 25, 2015
Nov. 25 — Turing Pharmaceuticals LLC CEO Martin Shkreli discusses the pricing of the company’s pharmaceuticals. He speaks on “Bloomberg Markets.”

Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.

Sheeraz Raza
Editor

Related news

S&P 500 Hits All-Time High as Q2 Earnings Season Kicks Off
Dave Kovaleski
Inflation rate
Inflation Falls to 3% in June – A Kickstarter for Rate Cuts?
Dave Kovaleski
Jerome Powell discussed interest rate decisions
Fed Chair Jerome Powell: “Two-Sided Risks” to Interest Rate Decisions
Dave Kovaleski
FOMC Member
There are ‘Several Reasons’ to Be Optimistic About Inflation, According to FOMC Member
Dave Kovaleski
Inflation Rates
How Low Will Inflation Rates Be One Year From Now?
Dave Kovaleski

Must Read

New

How to Invest in Stocks in 2024 – Beginner’s Guide

Investing in stocks can be a great way to improve your overall wealth – but...

23 Min Read Read now

Latest News

ETFs

BlackRock Profits Jump 10%: 3 Takeaways from Q2 Earnings
Dave Kovaleski14 hours

Blackrock set a record with $10.6 trillion in assets under management in the second quarter, led by high ETF flows. BlackRock (NYSE:BLK) stock was trending up Monday after the asset...

Categories

Want Financial Guidance Sent Straight to You?

  • Pop your email in the box, and you'll receive bi-weekly emails from ValueWalk.
  • We never send spam — only the latest financial news and guides to help you take charge of your financial future.